secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2026-08-06T12:00:37+00:00
Accession:  0001171843-26-005294
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q2 net loss narrows to $1.5M; cash runway through Q4 2026
----------------------------------------------------------------

- Net loss of $1.5M ($0.14 per share) vs $15.9M ($1.53) in Q2 2025; improvement driven by $3.0M warrant fair value gain.
- Cash, equivalents and investments $30.4M at June 30, 2026, down from $77.8M at Dec 31, 2025; expects funding through Q4 2026.
- Received $25M upfront from Amoytop for Greater China license of pevifoscorvir sodium; $3M milestone from ALG-170675 IND approval expected Q3 2026.
- Phase 2 B-SUPREME study of pevifoscorvir sodium fully enrolled (245 participants); topline data expected late Q3 2027.
- R&D expenses rose to $24.1M from $14.0M due to Phase 2 trial costs; G&A flat at $5.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/0001171843-26-005294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/f8k_080526.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer